Substance / Medication

Efanesoctocog alfa

Overview

Active Ingredient
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
RxNorm CUI
2631084

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.
Álvarez Román María Teresa, Kragh Nana, Guyot Patricia et al. · Adv Ther · 2025
PMID: 39576432Meta-AnalysisFull text (PMC)
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies.
Klamroth Robert, von Drygalski Annette, Hermans Cedric et al. · Haemophilia · 2025
PMID: 40099428TrialFull text (PMC)
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
Malec Lynn, Peyvandi Flora, Chan Anthony K C et al. · N Engl J Med · 2024
PMID: 39018533Trial
Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.
DiBenedetti Dana, Neme Daniela, Pan-Petesch Brigitte et al. · Clin Ther · 2024
PMID: 39414418Trial
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski Annette, Chowdary Pratima, Kulkarni Roshni et al. · N Engl J Med · 2023
PMID: 36720133Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Efanesoctocog alfa (substance)
SNOMED CT
1363054004
UMLS CUI
C5421030
RxNorm CUI
2631084

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.